Hims & Hers Health Inc Stock Price, News & Analysis

Hims & Hers Health reported strong Q4 2021 results, with revenues of $84.7 million, up 104% YOY, and full-year revenues of $271.9 million, marking an 83% increase. However, net losses widened to $(31.2) million in Q4 and $(107.7) million for the year. The company ended the year with 609,000 subscriptions, a 95% YOY growth. Looking ahead, guidance for 2022 suggests revenues between $365 million and $380 million but projects Adjusted EBITDA losses between $(30) million and $(20) million.

Hims & Hers Health, Inc. (NYSE: HIMS) announces a new partnership with GNC Holdings to enhance consumer access to health and wellness products. Selected products will be available in GNC stores and online at GNC.com. This collaboration aims to broaden the brand's reach across the U.S., providing consumers with easier access to offerings such as hair care solutions. Hims & Hers now partners with over a dozen retail brands, totaling more than 20,000 locations, reinforcing its mission for mass market accessibility.

Hims & Hers Health (NYSE: HIMS) has launched three new wellness supplements aimed at enhancing mental wellness, targeting issues like stress, sleep disturbances, and lack of focus. The products—Mind Unwind, Double Doze, and Focus Finder—are available via their website and select retailers such as Target and Walgreens. Each supplement incorporates natural ingredients to support consumer wellness journeys, including innovative formulations for prolonged effects.

Hims & Hers Health, Inc. (NYSE: HIMS) will announce its fourth quarter and fiscal year 2021 financial results on February 22, 2022, at 4:00 PM E.T. A conference call will immediately follow at 5:00 PM E.T.. Investors can join the call by dialing +1 (888) 510-2630 for U.S. participants or +1 (646) 960-0137 for international callers, using conference ID #1704296. A live audio webcast will also be available online, with a replay accessible for 12 months. Hims & Hers provides telehealth services across all 50 states, focusing on primary care, mental health, sexual health, and dermatology.

Hims & Hers Health, Inc. (NYSE: HIMS) has launched its mobile app, enhancing access to modern healthcare for over 500,000 subscription members. The app offers features such as guided programs, 24/7 concierge support, and a curated member store. CEO Andrew Dudum highlighted this launch as a key step in reshaping healthcare experiences. Users can manage treatments, access medical experts, and engage in community Q&As directly through the app. This initiative aims to provide a supportive, holistic approach to health and wellness.

Hims & Hers Health has announced the launch of its hair loss solutions in collaboration with Walmart. This partnership will allow customers access to a variety of products like minoxidil solutions and shampoos in select Walmart stores and online. The products cater to a significant market, addressing hair loss experienced by 1 in 3 women and two-thirds of men by age 35. Hims & Hers aims to enhance its reach and accessibility, reinforcing its commitment to providing convenient health and wellness solutions to consumers.

Hims & Hers Health, Inc. (NYSE: HIMS) has announced key leadership changes to enhance its growth trajectory in the telehealth industry. Yemi Okupe, a finance veteran with experience at PayPal, eBay, and Uber, will assume the role of Chief Financial Officer on January 24, 2022. Dr. Patrick Carroll, the current Chief Medical Officer, is appointed to the Board of Directors. The company's strategic focus remains on transforming healthcare and wellness, reporting a 79% revenue growth to $74.2 million in Q3 2021, and expanding its market presence in underpenetrated sectors valued at $65 billion.

Hims & Hers Health (NYSE: HIMS) has launched two new prescription products targeting hair loss in women: Topical Finasteride & Minoxidil Spray and Oral Spironolactone. This development aims to address a common issue affecting 30 million women in the U.S. The topical spray combines clinically proven ingredients for easy application, while the oral pill is designed to slow shedding and promote regrowth. These offerings respond to an increasing demand for effective hair loss treatments, with internet searches for hair loss rising 8% over the past year.

Hims & Hers Health, Inc. has appointed Jay Spitzer as the new Senior Vice President of Investor Relations, bringing over a decade of experience from Walgreens Boots Alliance. The company reported 79% revenue growth to $74.2 million in Q3 2021, with a 95% increase in subscribers, now totaling 551,000. Additionally, partnerships with major brands such as Amazon and Uber were announced. Hims & Hers is set to launch a new mobile platform aimed at enhancing health services.